Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Supreme Court to Hear Cisco Appeal on Alien Tort Statute and Human Rights Liability 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
BlackRock to Cut Around 250 Jobs as CEO Larry Fink Pushes Strategic Shift 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
UBS Upgrades L’Oréal to Buy, Sees Strong Sales Momentum and 20% Upside 
China’s AI Sector Pushes to Close U.S. Tech Gap Amid Chipmaking Challenges 
Nvidia Denies Upfront Payment Requirement for H200 AI Chips Amid China Export Scrutiny 
Chevron Sees Path to Boost Venezuela Oil Output by 50% After Trump Administration Talks 
FTC Blocks Edwards Lifesciences’ JenaValve Acquisition in Major Antitrust Ruling 
Trump Calls for 10% Credit Card Interest Rate Cap Starting 2026 
Stellantis to End Plug-In Hybrid Sales in the U.S. as Demand Shifts Toward Traditional Hybrids 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
Allegiant to Acquire Sun Country Airlines in $1.5 Billion Deal to Expand U.S. Leisure Travel Network 
PLANO, Texas, March 27, 2017 -- Nuvectra Corporation (NASDAQ:NVTR), a neurostimulation medical device company, announced today that Cowen and Company and The Ruth Group are hosting a physician panel on the spinal cord stimulation market and the Algovita system. The event will feature discussions with Jeffery Rowe, MD, and Brian Bannister, MD, and will be moderated by Cowen medical technology analyst Josh Jennings, MD.
| Event: | Spinal Cord Stimulation Physician Panel |
| Date: | Wednesday, March 29, 2017 |
| Time: | 12:00 pm ET |
| Location: | Cowen and Company Offices; 599 Lexington Ave, New York |
A webcast of the event will be available by visiting the investor relations section of Nuvectra’s website at www.nuvectramed.com.
If interested in attending the live event please contact your Cowen sales representative or The Ruth Group.
Participating Physicians
Jeffery Rowe, MD is a practicing physician at Main Line Spine in King of Prussia Pennsylvania, a comprehensive care center for spine related conditions and injuries. Dr. Rowe attended medical school at Saba University School of Medicine. Upon completing medical school he entered a General Surgery residency at Medical College of Pennsylvania/Hahnemann University before beginning his Physical Medicine and Rehabilitation residency at University of Pennsylvania. Following residency he was fellowship trained in Interventional Spine and Pain Medicine. Dr. Rowe is board certified in Physical Medicine & Rehabilitation and in Pain Medicine. His professional interests include the management of complex pain related medical issues with minimally invasive injections through trial and surgically implanted spinal cord stimulators.
Brian Bannister, MD is a practicing physician at Progressive Pain Management in Monmouth County, NJ, where he takes a multimodal approaches to pain control using proven, innovative techniques, combined with compassionate and individualized care. Dr. Bannister attended medical school at the State University of New York, Upstate Medical University where he also completed a Fellowship in Pain Management and his residency in Clinical Anesthesiology. Dr. Bannister is board certified in Anesthesiology.
About Nuvectra Corporation
Nuvectra™ is a neurostimulation company committed to helping physicians improve the lives of people with chronic neurological conditions. The Algovita® Spinal Cord Stimulation (SCS) System is our first commercial offering and is CE marked and FDA approved for the treatment of chronic pain of the trunk and/or limbs. Our innovative technology platform also has capabilities under development to support other neurological indications such as sacral nerve stimulation (SNS), and deep brain stimulation (DBS). In addition, our NeuroNexus subsidiary designs, manufactures and markets leading-edge neural-interface technologies for the neuroscience clinical research market. Visit the Nuvectra website at www.nuvectramed.com.
Company Contacts: Nuvectra Corporation Walter Berger, Chief Operating Officer and Chief Financial Officer (214) 474-3102 [email protected] Jennifer Armstrong, Media Relations (214) 474-3110 [email protected] Investor Contacts: The Ruth Group Nick Laudico (646) 536-7030 [email protected] Zack Kubow (646) 536-7020 [email protected]
